Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma (Q39386060)

11 September 2017

Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma (English)

1 reference

11 September 2017

0 references

J Chen

1

1 reference

11 September 2017

B Yang

2

1 reference

11 September 2017

S Zhang

3

1 reference

11 September 2017

Y Ling

4

1 reference

11 September 2017

J Ye

5

1 reference

11 September 2017

Z Jia

6

1 reference

11 September 2017

J Cao

7

1 reference

11 September 2017

2 March 2012

1 reference

11 September 2017

1 reference

11 September 2017

19

1 reference

11 September 2017

5

1 reference

11 September 2017

328-335

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2012.5

11 September 2017

0 references

cites work

Tissue-specific promoters for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Cis-acting region associated with lung cell-specific expression of the secretory leukoprotease inhibitor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Transcriptional analysis of human survivin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Transductional targeting of adenovirus vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Current developments in adenovirus-based cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

RETRACTED ARTICLE. Localized synovial hypertrophy in the anteromedial compartment of the osteoarthritic knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

siRNA delivery systems for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Suicide genes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Viral vectors for gene transfer: current status of gene therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Therapeutic potential of AIF-mediated caspase-independent programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

BID as a double agent in cell life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

A significant increase of RNAi efficiency in human cells by the CMV enhancer with a tRNAlys promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

7 January 2021

Specific detection and quantitation of SCC antigen 1 and SCC antigen 2 mRNAs by fluorescence-based asymmetric semi-nested reverse transcription PCR

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

7 January 2021

Targeting p53 for Novel Anticancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

7 January 2021

Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.5

7 January 2021

Identifiers

DOI

10.1038/CGT.2012.5

1 reference

Dimensions Publication ID

11 September 2017

0 references

1 reference